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Effect of cotrimoxazole prophylaxis on the
incidence of malaria in HIV-infected
children in 2012, in Abidjan, Côte d’Ivoire: a
prospective cohort study
Aïda Mounkaila Harouna1,2*, Madeleine Amorissani-Folquet3,4, François Tanoh Eboua5, Sophie Desmonde1,2,
Sylvie N’Gbeche6, Edmond Addi Aka6, Kouakou Kouadio7, Brou Kouacou8, Karen Malateste1,2, Clarisse Bosse-Amani8,
Patrick Ahuatchi Coffie3,9, Valeriane Leroy1,2 and for the IeDEA paediatric West African Study Group
Abstract
Background: Cotrimoxazole prophylaxis has an antimalarial effect which could have an additional protective effect
against malaria in HIV-infected children on antiretroviral therapy (ART). We measured the incidence and associated
factors of malaria in HIV-infected children on ART and/or cotrimoxazole in Abidjan, Côte d’Ivoire.
Methods: All HIV-infected children <16 years, followed-up in the IeDEA West-African paediatric cohort (pWADA) in
Abidjan, were prospectively included from May to August 2012, the rainy season. Children presenting signs
suggesting malaria had a thick blood smear and were classified as confirmed or probable malaria. We calculated
incidence density rates (IR) per 100 child-years (CY). Risk factors were assessed using a Poisson regression model.
Results: Overall, 1117 children were included, of whom 89 % were ART-treated and 67 % received cotrimoxazole.
Overall, there were 51 malaria events occurring in 48 children: 28 confirmed and 23 probable; 94 % were
uncomplicated malaria. The overall IR of malaria (confirmed and probable) was 18.3/100 CY (95 % CI: 13.3-23.4),
varying from 4.2/100 CY (95 % CI: 1.1-7.3) in children on ART and cotrimoxazole to 57.3/100 CY (95 % CI: 7.1-107.6)
for those receiving no treatment at all. In univariate analysis, age <5 years was significantly associated with a 2-fold
IR of malaria compared to age >10 years (incidence rate ratio [IRR] = 2.18, 95 % CI: 1.04-4.58). Adjusted for severe
immunodeficiency, cotrimoxazole reduced significantly the IR of first malarial episode (adjusted IRR [aIRR] = 0.13, 95
% CI: 0.02-0.69 and aIRR = 0.05, 95 % CI:0.02-0.18 in those off and on ART respectively). Severe immunodeficiency
increased significantly the malaria IR (aIRR = 4.03, 95 % CI: 1.55-10.47).
When considering the IR of confirmed malaria only, this varied from 2.4/100 CY (95 % CI: 0.0-4.8) in children on ART
and cotrimoxazole to 34.4/100 CY (95 % CI: 0.0-73.3) for those receiving no treatment at all. In adjusted analyses,
the IR of malaria in children on both cotrimoxazole and ART was significantly reduced (aIRR = 0.05, 95 % CI: 0.01-0.24)
compared to those receiving no treatment at all.
Conclusions: Cotrimoxazole prophylaxis was strongly protective against the incidence of malaria when associated with
ART in HIV-infected children. Thus, these drugs should be provided as widely and durably as possible in all HIV-infected
children <5 years of age.
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Background
In 2010, approximately 216 million malaria episodes oc-
curred worldwide, 81 % of which were in sub-Saharan
Africa. Overall, 655,000 of these cases led to death, 86 %
occurring in children under five years [1]. That same
year, there were approximately 3.4 million children
under fifteen years living with HIV worldwide of which
more than 90 % lived in sub-Saharan Africa [2]. Malaria
and HIV are two infections with overlapping epidemio-
logic maps that to be addressed urgently.
There is an interaction between malaria and HIV in-
fections which causes a global health problem [3]. On
the one hand, HIV-related immunodeficiency results in
children being more vulnerable to malaria, reducing the
efficacy of antimalarial drugs [4, 5]. On the other hand,
malaria is known to increase viral replication and thus
HIV disease progression [3]. This interaction needs to
be further investigated in a context where access to
cotrimoxazole prophylaxis and antiretroviral therapy
(ART) could have a protective effect against malaria in
HIV infected-children [6, 7]. Although not defined as an
opportunistic disease [8, 4], a malarial episode may be-
come more serious with HIV influence as reported by
many studies mostly conducted in Southern and Eastern
Africa [5, 7, 9, 10]. Before the ART era, cotrimoxazole
prophylaxis reduced morbidity and mortality in children
with HIV by preventing bacterial infections, diarrhea,
malaria, and Pneumocystis jirovecii pneumonia, in
Zambia [11].
In Côte d’Ivoire, malaria is the first cause of morbidity
and mortality in children: the incidence was 288 ‰ in
2012 [12] in children under five years and represented in
2010, 25 % of death causes [13]. Moreover, in 2009, HIV
represented 4.4 % of deaths in children under five in
Côte d’Ivoire [2]. Despite this, the incidence of malaria
in HIV-infected children, treated or not, has never been
documented in West Africa, where the malaria endemic,
microbial resistance and HIV prevalence are different
compared to other regions. The main objective of this
study was to measure the incidence of malaria and asso-
ciated factors in HIV-infected children on ART and/or
cotrimoxazole prophylaxis and who are followed-up in
HIV-care programmes in Abidjan, Côte d’Ivoire.
Methods
Study sites
The paediatric West African Database on AIDS
(pWADA), a component of the International epidemio-
logic Databases to Evaluate AIDS (IeDEA), is a multi-
cohort collaboration including 11 paediatric HIV-care
programmes in seven West African countries, including
five centres in Abidjan. The main objective of this co-
hort collaboration is to document the long-term morbid-
ity, mortality and retention of HIV-infected children
under 16 years [14]. In each centre, HIV-infected chil-
dren are seen in the context of a routine visit at least
once every three months and/or because they present
symptoms requiring clinical care. CD4 counts are mea-
sured every six months. Viral load is not routinely moni-
tored. ART, cotrimoxazole prophylaxis and HIV-related
blood analyses are free of charge. However, other health
care benefits are partially or fully paid for by patient.
The present study, called PALUVIH (Malaria and HIV
study), was conducted within the five centres of
pWADA cohort in Abidjan: two in Yopougon (the
Centre pédiatrique de Prise en charge, de Recherche et
de Formation [CePReF-enfant] and the paediatric cohort
of the Yopougon University Hospital), one in Treichville
(the Centre Intégré de Recherche Bioclinique d’Abidjan
[CIRBA]), one in Cocody (the paediatric cohort of the
Cocody University Hospital) and one in Abobo (the
Mother To Child Transmission centre [MTCT-Plus]). In
2012, the incidence of malaria in Abidjan varied in the
general population, ranging from 215 ‰ in Cocody area
to 112 ‰ for Yopougon; in Treichville it was 118 ‰ and
185 ‰ in Abobo. Thus, Cocody and Abobo districts were
a 2-fold higher endemic areas for malaria compared to
other districts in Abidjan [12].
Study design and patient population
We conducted a prospective cohort study, nested in the
Abidjan pWADA cohort, from May to August 2012
during the first rainy season of the year, favourable to
the reproduction of mosquitoes (malaria vectors). In
Abidjan, there are two rainy seasons: May-July and
October-November.
All HIV-infected children (aged <16 years) followed-
up within pWADA and who attended, for any reason, at
least once one of the five centres during the study period
were included in the PALUVIH cohort from 7th May
2012 (the date of the routine implementation of malaria
documentation) and were followed-up until 6th August
2012. In the pWADA cohort, children with any inter-
current clinical symptoms between two per-protocol
visits, which are at three-month intervals, can attend
their centre.
During the PALUVIH study period, we prospectively
documented all clinical episodes at any per-protocol or
inter current visits evoking malaria in children included
(fever, chills, aches, headache, diarrhoea, vomiting, irritabil-
ity, confusion…), with a thick blood smear, the first-line
exam recommended by WHO and the Ivoirian National
Program to diagnose malaria [15].
Definition
The outcome was the incidence of incident malaria, de-
fined according to WHO, as follows [16, 17]:
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According to the embodiment of thick blood smear:
confirmed malaria (clinical symptoms suggesting malaria
documented by a positive thick blood smear) and prob-
able malaria (clinical events without laboratory confirm-
ation or negative thick blood smear but solved by an
antimalarial treatment).
According to the presence or not of clinical or bio-
logical severity signs of malaria: uncomplicated malaria
(no clinical or biological signs of severity) and severe
malaria (one or more of the following clinical or bio-
logical signs of severity: consciousness disorders (Blan-
tyre coma scale ≤3), prostration, inability to eat, >2
convulsions/24 h, respiratory distress, cardiovascular
collapse, clinical jaundice accompanied by other signs of
vital organ dysfunction, oliguria <0.5 mL/kg/h, serum
créatinine >265 μmol/L, haemoglobinuria, spontaneous
bleeding disorders, pulmonary oedema, hypoglycemia
(<2.2 mmol/L), metabolic acidosis (bicarbonate <15 mmol/
L); severe anaemia (Hb <5 g/dL); hyperparasitemia (>5 %)
and hyperlactacidemia (lactic acid >5 mmol/L)) [15].
A recurrent event of malaria was defined as any malar-
ial event occurring in a child who had already presented
malaria during the study period and for whom the event
had been resolved, confirmed by a negative control.
Thick blood smears and all complementary tests (para-
sitemia, biochemistry and hematology tests) and anti-
malarial treatments were paid by the PALUVIH project
and there were no extra costs for patient families. Cases
of uncomplicated malaria were treated per os by
Artesunate-Amodiaquine or Artemether-Lumefantrine
association and complicated cases with injectable Arte-
mether or Quinine Resorcine.
Ethical approval
The IeDEA West Africa collaboration was approved
by the national ethics committees of each participating
country and the name of the Ivoirian ethics committee
where this study took place is as follows : “Comité Na-
tional d’Ethique et de la Recherche de République de
Côte d’Ivoire”. As care was conducted according to
the national standard of care recommended, individual
informed signed consent was waived for this sub-
study.
Data collection
Data were collected retrospectively and prospectively
using two collection instruments:
Socio-demographic and HIV-infection data for all
children at the time of the PALUVIH study inclusion
were extracted from the pWADA databases (birth’s
date; HIV type; last CD4 cell count, or percentage
available and date);
A register was used to collect prospectively during the
study period for all children, date and reason of consult-
ation, ongoing cotrimoxazole and ART regimen;
A standardized form was used prospectively for all
children presenting any sign suggesting malaria to col-
lect the following data: clinical symptoms; temperature;
insecticide-treated bed-nets use; taking medication be-
fore consultation; paraclinical examination results (thick
blood smear and parasitemia, full blood count,…); exist-
ence of clinical or biological severity signs; existence of any
comorbidity; malaria episode management (hospitalization,
outpatient treatment); evolution of the malaria episode
(control thick blood smear performed 14 days after
antimalarial treatment start, healing, short-term sequelae,
death).
Data management and statistical analysis
Categorical variables were presented as frequencies
and continuous variables as median with Interquar-
tile Range (IQR).
Incidence density rates (IR) of all malaria events (con-
firmed and probable, then only confirmed to provide
conservative estimates), including both first and recur-
rent events, were calculated per 100 child-years of
follow-up (CY) with their 95 % Confidence Interval (95
% CI) according to the Miettinen formula [18]. Each
child included contributed to the denominator for the
three-month study period (from May to August 2012) or
until the death if this occurred earlier. The baseline
characteristics were defined at time of inclusion (7th
May 2012). Factors associated with the incidence of first
case of malaria were identified by a Poisson regression
model including the following co-variables: cotrimoxazole,
ART, age group (<5 years, [5-10[years and ≥10 years) and
immunodeficiency for age at the time of visit (+/−
3 months) (severe, moderate and no immunodeficiency).
We defined severe immunodeficiency for age according to
the 2010 WHO recommendations for ART initiation [19]
as follows: CD4 < 25 % if aged < 1 year; CD4 < 20 % if aged
between [1–3 years[; CD4 < 15 % if aged between [3-
5years[; CD4 < 200/mm3 if aged ≥5 years. Moderate im-
munodeficiency was defined as follow: CD4 [25 %-35 % [if
aged <1 year; CD4 [20 %-30 %[if aged [1–3 years[; CD4
[15 %-25 %[if aged between [3-5years[; CD4 between
[200/mm3-500/mm3 [if aged ≥5 years. This regression
analysis was first conducted with all malaria cases, and
then only confirmed malaria cases in a sensitivity
analysis.
Because children could present more than one malaria
episode during the study period, we limited this specific
analysis to the incidence of the first episode. We first
ran univariate analyses for each co-variable, and then
ran a full multivariate model estimating adjusted inci-
dence rate ratio (aIRR). Due to the small number of
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events, only major explanatory variables were kept in
multivariate analyses allowing the model to converge.
Thus, the adjusted model included only the following
covariates: ART (forced as the main explanatory vari-
able), cotrimoxazole and severe immunodeficiency for
age. Data were entered using Microsoft Access 2003 and
statistical analyses were performed using Epiinfo version
3.5.3 and SAS version 9.3.
Results
Baseline characteristics
Overall, 1117 children were included. Children aged <5 years
accounted for 13 % of the population and had a me-
dian CD4 % of 29 % (IQR: 24–35) while older children
aged ≥5 years had 781 CD4 cells/mm3 (IQR: 507–
1084). In the MTCT-Plus centre, 28 % of the included
children were under five compared to the other centres
where this proportion was on average 12 % (p < 0.01).
Cotrimoxazole prophylaxis was prescribed to 67 % of
the children and ART to 89 % among whom 84 %
received a Non-Nucleoside Reverse Transcriptase In-
hibitor (NNRTI)-based regimen and 14 % a Protease-
Inhibitor (PI)-based regimen (Table 1).
Malaria cases description and evolution
During the study, 48 children presented 51 malaria at-
tacks; three children had a recurrent episode. Six chil-
dren (13 %) used an insecticide-treated bed-net at the
time of the event; but this information was not available
for the whole sample.
Seven children (15 %) were administered by their care-
givers a known antimalarial drug before consultation, of
whom six had taken Artemeter-Luméfantrine or
Artesunate-Amodiaquine.
Among the 51 cases of malaria, 28 were confirmed by
a thick blood smear and the median parasitemia was
1800/μL (IQR: 440–4210); the 23 remaining cases were
classified as probable malaria. Complete blood counts
were performed for 30 children, among which median
haemoglobin (Hb) was 10.2 g/dL (IQR: 8.8-11.3) and
80 % had haemoglobin <12 g/dL.
Overall, 48 of the 51 diagnoses were uncomplicated
malaria, among them, eight were treated in outpatient
day-care hospitals and for the remaining 40, stander out-
patient treatment was the modality of care. The three
cases of severe malaria were treated with hospitalization.
Among these severe malarial events, two were associated
with severe anemia (Hb <7 g/dl) and one with a cardio-
vascular collapse. The overall distribution of antimalarial
treatment prescriptions were as follows: Arthemether-
Lumefrantrine per os (42 %); Artesunate-Amodiaquine
per os (35 %); Arthemether injections (13 %); Quinine in-
jections (10 %). In eleven cases, unknown antibiotics were
prescribed in addition to the antimalarial treatment. None
of the malarial events led to death. Of the 28 cases of con-
firmed malaria, 75 % of thick blood smears were con-
trolled two weeks after the beginning of the antimalarial
treatment, of which two came back positive.
Incidence density rates of malaria
The overall IR of malaria (confirmed and probable) was
estimated to be 18.3/100 CY (95 % IC: 13.3-23.4). IRs
increased from 4.2/100 CY (95 % CI: 1.1-7.3) in children
on ART and cotrimoxazole to 57.3/100 CY (95 % CI:
7.1-107.6) in those without ART or cotrimoxazole. It
was 14.5/100 CY (95 % CI: 0.0-30.9) in children on
cotrimoxazole.
The IR in children with severe immunodeficiency
for age was 29.4/100 CY (95 % CI: 3.6-55.2) and 17.0/
100 CY (95 % CI: 11.7-22.3) in those without severe
immunodeficiency.
Among children under five, the IR was 30.7/100 CY
(95 % CI: 12.5-48.8) and 18.1/100 CY (95 % CI: 10.2-26.1)
in children aged between [5–10 years].
Compared to the other sites, MTCT-Plus had the high-
est observed IR of 77.5/100 CY (95 % CI: 31.7-123.2)
(Table 2).
When considering only confirmed malaria cases, IR
were lower (Table 2).
Factors associated with the incidence of the first malaria
event
When analysing the 48 cases of first malaria episode
(confirmed and probable), in univariate analyses, com-
pared to children receiving no treatment at all, the inci-
dence of malaria was respectively reduced by 93 %
among children receiving both cotrimoxazole prophy-
laxis and ART (incidence rate ratio [IRR]: 0.07, 95 % CI:
0.02-0.21) and by 84 % in those on cotrimoxazole alone
(IRR: 0.16, 95 % CI: 0.03-0.80), (Table 3).
There was a non-significant trend to a higher mal-
aria incidence in severely immunodeficient children
compared to those not immunodeficient (IRR: 1.87,
95 % CI: 0.73-4.76).
Age < 5 years was also significantly associated with a
higher incidence of malaria (IRR: 2.18, 95 % CI: 1.04-
4.58) compared to children aged > 10 years. Incidence of
malaria was also significantly associated with the follow-
up clinic (p < 0.01): the MTCT-Plus care centre where
the children were also the youngest with a median age
of two years, was significantly associated with a higher
incidence of malaria (IRR: 38.72, 95 % CI: 5.00-299.97).
Unfortunately, due to the low number of malaria
events, our model did not converge in multivariate ana-
lyses, when including in the final model all of the above
variables associated in univariate analysis. Thus, we pri-
vileged the analysis of the effect of ART and
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cotrimoxazole adjusted on the severe immunodeficiency
to further explore our question while the effect of age is
already well known.
In the multivariate analysis adjusted for both severe
immunodeficiency and ART, cotrimoxazole prophylaxis
either alone or in combination with ART reduced sig-
nificantly the risk of malaria by 87 %, (adjusted incidence
rate ratio [aIRR]: 0.13, 95 % CI: (0.02-0.69), and 95 %
(aIRR: 0.05, 95 % CI: 0.02-0.18), respectively) (Table 3).
ART alone tended to reduce the incidence of malaria
by 31 % (aIRR: 0.69 (95 % CI: 0.27-1.77) but this reduction
was not statistically significant. The adjusted incidence of
malaria was significantly highest in children with severe
immunodeficiency for age when adjusted for ART and
cotrimoxazole prophylaxis (aIRR = 4.03, 95 % CI: 1.55-
10.47) (Table 3).
When conducting the analysis only including the con-
firmed cases, malaria incidence was no longer reduced in
children on cotrimoxazole alone in the univariate analysis
(IRR: 0.13, 95 % CI: 0.01-1.25) (Table 4). We observed
similar results in the multivariate analyses, adjusted for
immunodeficiency, where cotrimoxazole prophylaxis in
combination with ART still reduced significantly the risk
of malaria by 95 %, (adjusted incidence rate ratio [aIRR]:
0.05, 95 % CI: (0.01-0.24), but the use of cotrimoxazole
alone was not longer significantly associated with malaria
(aIRR: 0.11 (95 % CI: 0.01-1.08) (Table 4).
Discussion
To our knowledge, this study is the first to specific-
ally describe the association between the intake of
cotrimoxazole prophylaxis and the incidence of mal-
aria in HIV-infected children in several care pro-
grams in Abidjan. It has allowed documenting in a
standardized manner any suspected malaria cases
among HIV-infected children. We reported a high
incidence rate of malaria (18.3/100 CY) that was
strongly reduced in children on cotrimoxazole alone
or combined with ART when adjusting for severe
immunodeficiency. Incidence of malaria was twice as
high in children under five years compared to those
older than 10 years. The incidence of malaria was
Table 1 Baseline characteristics of the 1117 HIV-infected
children included in the pWADA cohort, Abidjan, May-
August 2012
Characteristics (N = 1117) n (%)
Centre participants, n (%)
Cocody University Hospital 182 (16.3)
Yopougon University Hospital 344 (30.8)
CePReF 322 (28.8)
CIRBA 212 (19.0)
MTCT+ 57 (5.1)
Total site 1117 (100.0)
Age (years)
Median (IQR) 9 (6–12)
Sex, n (%)
Male 553 (49.5)
Female 564 (50.5)
HIV type, n (%)
1 1111 (99.4)
2 4 (0.4)
1 & 2 2 (0.2)
Last CD4 measurement available
at the time of the visit
Percentage when age
< 5 years n (%)
144 (13.0)
Median CD4 % (IQR) 29 (24–35)
CD4 > 35 %, n (%) 34 (23.6)
25 % ≤ CD4≤ 35 %, n (%) 66 (45.8)
CD4 < 25 %, n (%) 40 (27.8)
Missing, n (%) 4 (2.8)
Cell count when age
≥ 5 years n (%)
973 (87.0)
Median CD4 cells/mm3, (IQR) 781 (507–1084)
CD4 > 500 cells/mm3, n (%) 731 (75.1)
350≤ CD4≤ 500 cells/mm3, n (%) 102 (10.5)
CD4 < 350 cells/mm3, n (%) 140 (14.4)
Missing, n (%) 0 (0.0)
Treatment received at the
time of the visit
On ART – On Cotrimoxazole 667 (59.7)
Off ART – On Cotrimoxazole 83 (7.4)
On ART – Off Cotrimoxazole 323 (29.0)
Off ART – Off Cotrimoxazole 35 (3.1)
On ART unknown for
Cotrimoxazole
9 (0.8)
ART drugs regimen
2 NRTIa + 1 NNRTIb 842 (84.3)
2 NRTI + 1 PIc 144 (14.4)
3 NRTI 9 (0.9)
Table 1 Baseline characteristics of the 1117 HIV-infected
children included in the pWADA cohort, Abidjan, May-
August 2012 (Continued)
Missing 4 (0.4)
Median follow-up time on ART (year) (IQR) 2.2 (0.4-5.2)
Median follow-up time on Cotrimoxazole (year) (IQR) 3.4 (1.3-6.1)
n: number; ART: antiretroviral therapy; NRTIa: Nucleoside Reverse Transcriptase
Inhibitors. INNRTb: Non-Nucleoside Reverse Transcriptase Inhibitors. PIc:
Protease Inhibitors
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not reduced in children treated with ART only com-
pared to those not on ART.
Our study was conducted in a substantial sample size
of more than 1000 HIV-infected children during the
rainy season, a high transmission period of malaria.
However, we also note study limitations. First, our esti-
mation of the incidence of malaria is likely to have been
underestimated for several reasons: due to logistical
reasons, our study period did not cover the entire rainy
season, which usually ends in November. We only docu-
mented all clinically driven symptoms but did not per-
formed routine thick smears in asymptomatic children.
We may also have missed malaria cases because they
could have been treated outside the study centres or be-
cause of self-medication for malaria before seeking care,
which is often practiced in Côte d’Ivoire, as reported in
Table 2 Incidence density rates of malaria per 100 child-years of follow-up in the 1117 HIV-infected children included in the pWADA
cohort, Abidjan, May-August 2012
Characteristics N Number
of
child-
years of
follow-
up
Incidence density rate with 95 % Confidence
Interval for all cases of malaria: probable,
confirmed including recurrences
Incidence density rate with 95 % Confidence
Interval for confirmed malaria including
recurrences
n (%) Incidence density rate
(per 100 child-years)
(95 % Confidence
Interval)
n’ (%) Incidence density rate
(per 100 child-years)
(95 % Confidence
Interval)
Incidence density rate of malaria
Cases without
recurrences
1117 278 48 (94.1) 17.2 (12.4-22.1) - - -
Recurrence cases 1117 278 3 (5.9) 1.1 (0.0-2.3) - - -
Confirmed 1117 278 28 (55.0) 10.1 (6.3-13.8) - - -
Probable 1117 278 23 (45.0) 8.3 (4.9-11.6) - - -
Overall (confirmed and
probable)
51 (100.0) 18.3 (13.3-23.4) - - -
1117 278
Incidence density rate of
malaria according to treatment
On ART – On
Cotrimoxazole
667 166 7 (13.7) 4.2 (1.1-7.3) 4 (14.3) 2.4 (0.0-4.8)
Off ART – On
Cotrimoxazole
83 21 3 (5.9) 14.5 (0.0-30.9) 2 (7.1) 9.7 (0.0-23.1)
On ART – Off
Cotrimoxazole
323 80 36 (70.6) 44.7 (30.1-59.3) 19 (67.9) 23.6 (13.0-34.2)
Off ART – Off
Cotrimoxazole
35 9 5 (9.8) 57.3 (7.1-107.6) 3 (10.7) 34.4 (0.0-73.3)
Immunodeficiency
according to agea
Severe 69 17 5 (9.8) 29.4 (3.61-55.2) 3 (10.7) 17.5 (0.0-37.2)
Moderate 106 26 6 (11.8) 23.1 (4.6-41.5) 4 (14.3) 15.1 (0.3-30.0)
No/Missing 942 235 40 (78.4) 17.0 (11.7-22.3) 21 (75.0) 8.9 (5.1-12.8)
Age
<5 years 144 36 11 (21.6) 30.7 (12.5-48.8) 6 (21.4) 16.7 (3.3-30.1)
[5-10[years 443 110 20 (39.2) 18.1 (10.2-26.1) 12 (42.9) 10.9 (4.7-17.0)
≥10 years 530 132 20 (39.2) 15.1 (8.5-21.8) 10 (35.7) 7.6 (2.9-12.3)
Centres
University hospital
of Cocody
182 45 1 (2.0) 2.2 (0.0-6.5) 1 (3.6) 2.2 (0.0-6.5)
University hospital
of Yopougon
344 86 9 (17.6) 10.5 (3.6-17.4) 4 (14.3) 4.7 (0.1-9.2)
CePReF 322 80 23 (45.1) 28.7 (17.0-40.4) 11 (39.3) 13.7 (5.6-21.8)
CIRBA 212 53 7 (13.7) 13.3 (3.4-23.1) 2 (7.1) 3.8 (0.0-9.0)
MTCT-Plus 57 14 11 (21.6) 77.5 (31.7-123.2) 10 (35.7) 70.4 (26.8-114.1)
aUsing te 2010 WHO definition. ART: antiretroviral therapy; n’() number and percentage of only confirmed malaria cases
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15 % of the cases in our study. This could have led to
false negative results of the thick blood smear performed
also contributing to underestimation of the incidence of
malaria. Second, in this study we used the gold standard
for malaria diagnosis, which is microscopy. In a high en-
demic setting, where the population is immunocom-
promised, the use of additional laboratory tests such as
rapid diagnostic testing or PCR could have allowed iden-
tifying additional cases of malaria, but this was not feas-
ible for logistical reasons. Finally, there may also be a
classification bias over-estimating the incidence of mal-
aria: we defined probable malaria as any clinical event
evoking malaria and solved by antimalarial, however
23 % were co-treated with antibiotics which could indi-
cate that the event may have been another infection,
solved by the antibiotics the child was co-treated with.
Nevertheless, we conducted this study over a short
period of time with a previous awareness campaign
among the medical staff to improve and standardise all
the diagnosis procedures of malaria. Consequently we
conclude that our estimation is quite a reasonable min-
imal estimate. Unfortunately, also for logistical reasons,
it was no feasible to compare these results with a group
of HIV-uninfected children in the same community.
In our study, the global incidence of malaria (con-
firmed and probable) in HIV-1-infected children was
183 ‰ and 307 ‰ in children under five, respectively.
This estimation seems to be higher than others reported
in Cote d’Ivoire. The country is ranked the fifth among
countries most affected by malaria compared to the rest
of the world with an incidence estimated to be 116 ‰ in
the general population in 2012, with a similar risk in
children less than five: 288 ‰ [12]. In this same context,
a previous study conducted in HIV-infected children be-
fore ART initiation estimated a morbidity incidence of
66 ‰ attributable to malaria cases based on a syndromic
approach [20]. Our study shows a significant association
between malaria incidence and cotrimoxazole in HIV-
infected children with a strong independent protective
effect reducing by up to 87 % the risk of malaria as
shown by previous studies [21–26]. We also report that
the risk for malaria was significantly lower in those
treated with both ART and cotrimoxazole, reduced by
up to 95 % compared to those not treated. Mermin et al.
has also reported this previously in an adult population
in Uganda [27]. If used alone, ART tended to reduce the
incidence of malaria by 31 % in our study although this
was not statistically significant. Several other studies,
Table 3 Factors associated with the incidence of the first malaria event (n = 48) in the 1117 HIV-infected children included in the
pWADA cohort. Abidjan May-August 2012
N n Univariate analysis Adjusted analysis
IRR (95 % IC) p-value aIRR (95 % CI) p-value
Antiretroviral therapy (ART) and cotrimoxazole exposure <0.01 <0.01
On ART - On cotrimoxazole 667 7 0.07 (0.02-0.21) <0.01 0.05 (0.02-0.18) <0.01
Off ART - On cotrimoxazole 83 2 0.16 (0.03-0.80) 0.03 0.13 (0.02-0.69) 0.02
On ART - Off cotrimoxazole 332 34 0.69 (0.27-1.77) 0.44 0.69 (0.27-1.77) 0.44
Off ART - Off cotrimoxazole 35 5 1 - - 1 - -
Immunodeficiency for Agea 0.38 0.02
Severe 69 5 1.87 (0.73-4.76) 0.19 4.03 (1.55-10.47) <0.01
Moderate 106 6 1.44 (0.61-3.40) 0.41 2.14 (0.89-5.14) 0.09
No/Missing 942 40 1 - - 1 - -
Age 0.14
<5 years 144 11 2.18 (1.04-4.58) 0.04 Not included
[5-10[years 443 18 1.13 (0.59-2.16) 0.70
≥10 years 530 19 1 - -
Centres <0.01
CHU de Cocody 182 1 1 - -
CHU de Yopougon 344 9 4.80 (0.61-37.87) 0.14 Not included
CePReF 322 20 11.66 (1.56-86.91) 0.02
CIRBA 212 7 6.11 (0.75-49.65) 0.09
MTCT-Plus 57 11 38.72 (5.00-299.97) <0.01
N: number of children; n: number of malaria incident cases (confirmed and probable); IRR: incidence rate ratio; aIRR, adjusted incidence rate ratio; 95 % CI:95 %
Confidence Interval. aUsing the 2010 WHO definition
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conducted in vitro, have shown a significantly protective
effect of protease inhibitor drugs [28–31]. This differ-
ence could be explained by two factors: (i) a probable
lack of statistical power in our study; (ii) only 14 % of
our children were treated with a PI-based regimen
known to have a direct antimalarial activity [32].
Severe immunodeficiency is also known as a risk factor
for malaria [9, 33, 34]. Consistently, our results show
that children with severe immunodeficiency have a 4-
fold higher adjusted risk to develop malaria than those
not severely immunodeficient.
Children <5 years have a twice higher risk to develop
malaria in our study and this is expected and highly con-
sistent with what was reported by the WHO [1].
Our results suggest that cotrimoxazole provides an on-
going beneficial protection against malaria after immune
reconstitution in ART-treated children. This justifies its
use for all children even if they are receiving ART, with
a beneficial additive effect, as recommended by WHO
since 2000 [35].
Likewise, we reported the frequency of malaria occur-
rence in children already severely immunodeficient,
suggesting that the use of ART must be widespread to
all HIV-infected children with the aim to restore im-
munity as recommended by WHO in 2013 [36]. In
addition, children under five are most at risk for mal-
aria, extra attention should be given to this target
population by increasing, for example, the use of
insecticide-treated bed-nets in addition to treatments.
This latter measure remains an essential measure to
implement, as we reported that only 12 % of children
presenting malaria in our study used it in practice. This
use should significantly be improved to reduce malaria-
related morbidity and mortality in Africa [37].
Conclusion
In this study, we measured incidence density rates of
malaria in HIV-infected children and analysed its as-
sociated factors. Cotrimoxazole prophylaxis strongly
protected against malaria. We did not show a signifi-
cant association between incidence of malaria and
ART. But cotrimoxazole prophylaxis protection is
more important if used in addition to ART. Also,
immunodeficiency was an important risk factor of
malaria incidence suggesting that the indirect effect
of ART in restoring immunity justifies its use for all
HIV-infected children. These two drugs should be
provided as widely and as durably as possible in all
children, as recommended by WHO [36]. Likewise,
the provision of insecticide-treated bed-nets could
Table 4 Factors associated with the incidence of the first confirmed malaria event (n = 25) in the 1117 HIV-infected children
included in the pWADA cohort. Abidjan May-August 2012
N n Univariate analysis Adjusted analysis
IRR (95 % IC) p-value aIRR (95 % CI) p-value
Antiretroviral therapy (ART) and cotrimoxazole exposure <0.01 <0.01
On ART - On cotrimoxazole 667 4 0.06 (0.01-0.28) <0.01 0.05 (0.01-0.24) <0.01
Off ART - On cotrimoxazole 83 1 0.13 (0.01-1.25) 0.08 0.11 (0.01-1.08) 0.06
On ART - Off cotrimoxazole 332 17 0.58 (0.17-1.99) 0.38 0.58 (0.17-1.99) 0.39
Off ART - Off cotrimoxazole 35 3 1 - - 1 - -
Immunodeficiency for Agea 0.48 0.09
Severe 69 3 2.19 (0.65-7.39) 0.21 4.59 (1.32-15.98) 0.02
Moderate 106 3 1.40 (0.41-4.73) 0.59 2.09 (0.61-7.19) 0.24
No/Missing 942 19 1 - - 1 - -
Age 0.17
<5 years 144 6 2.82 (0.98-8.13) 0.05 Not included
[5-10[years 443 11 1.64 (0.66-4.09) 0.28
≥10 years 530 8 1 - -
Centres <0.01
CHU de Cocody 182 1 1 - -
CHU de Yopougon 344 4 2.13 (0.24-19.08) 0.50 Not included
CePReF 322 8 4.66 (0.58-37.30) 0.15
CIRBA 212 2 1.74 (1.56-19.25) 0.65
MTCT-Plus 57 10 35.20 (4.51-275.03) <0.01
N: number of children; n: number of malaria incident cases (only confirmed); IRR: incidence rate ratio; aIRR, adjusted incidence rate ratio; 95 % CI:95 % Confidence
Interval. aUsing the 2010 WHO definition
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reduce the incidence of malaria even further in chil-
dren under five, which are more affected by malaria.
These interventions will be helpful in reaching the
sixth millennium development goals to improve child
health [38].
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